Gramine Induces Ferroptosis in Triple-Negative Breast Cancer via the CUL3–MTDH Axis

Study Background and Research Question

Triple-negative breast cancer (TNBC) remains one of the most aggressive and therapeutically challenging subtypes of breast cancer, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. This molecular profile confers resistance to conventional targeted therapies, resulting in poor clinical outcomes and high recurrence rates. The urgent need for effective and selective interventions has driven interest in natural compounds with multi-target potential and favorable safety profiles. Gramine, a plant-derived indole alkaloid, has shown various pharmacological activities, but its detailed mechanisms in TNBC suppression were not fully elucidated. This study specifically investigates whether gramine can inhibit TNBC cell growth by inducing ferroptosis, and if so, through what molecular mechanisms involving the CUL3–MTDH axis.

Key Innovation from the Reference Study

The reference study introduces a novel mechanistic link between gramine exposure and induction of ferroptosis in TNBC cells. The key innovation lies in identifying that gramine directly targets the CUL3 (Cullin 3) E3 ubiquitin ligase, leading to altered ubiquitination and stabilization of MTDH (metadherin). This CUL3–MTDH axis orchestrates downstream modulation of ferroptosis regulators, representing a previously uncharacterized pathway for therapeutic intervention in TNBC. The mechanistic insight into CUL3-mediated ubiquitination as a regulator of ferroptosis in cancer is a valuable addition to the field of cancer biology and pharmacology.

Methods and Experimental Design Insights

The study employed a comprehensive screening of 27 structurally related indole alkaloids for anti-TNBC activity, using cell viability assays (CCK-8) to identify gramine as a lead compound. Target validation was accomplished through a suite of biophysical and biochemical approaches, including ligand-induced proteome mass spectrometry (LIP-MS), molecular docking simulations, cellular thermal shift assay (CETSA), and drug affinity responsive target stability (DARTS) assays. Western blotting quantified the expression levels of pivotal ferroptosis effectors and regulators, including MTDH, SLC3A2, and GPX4. Functional ferroptosis assays measured intracellular ROS, Fe²⁺, malondialdehyde (MDA), glutathione (GSH), and mitochondrial morphology. Rescue experiments (chemical inhibition of ferroptosis and MTDH knockdown) were performed to demonstrate mechanistic specificity. In vivo efficacy was validated using 4T1 and MDA-MB-231 xenograft mouse models, with assessment of tumor growth and systemic toxicity.

Protocol Parameters

• Gramine treatment: Administered at IC₅₀ ~22–28 μM for in vitro TNBC cell assays, as determined by CCK-8 viability screens.
• Target validation: LIP-MS and CETSA performed after gramine incubation to confirm direct binding; DARTS used to assess protease resistance of candidate proteins.
• Ferroptosis evaluation: Quantification of ROS, Fe²⁺, and MDA using established fluorescence and colorimetric assays; GSH depletion assessed by spectrophotometry.
• In vivo studies: 4T1 and MDA-MB-231 cells xenografted into immunodeficient mice; gramine administered at defined doses, with tumor volume and weight monitored over time.
• Protein expression analysis: Western blotting for MTDH, SLC3A2, and GPX4 following gramine exposure; β-actin or GAPDH used as loading controls.
• Ferroptosis rescue: Ferroptosis inhibitor (e.g., ferrostatin-1) and MTDH siRNA transfection applied to dissect pathway specificity.

Core Findings and Why They Matter

Gramine selectively inhibited the proliferation of TNBC cells at low micromolar concentrations, sparing non-malignant controls. Proteomic and biochemical analyses established that gramine directly binds to CUL3 and modulates its E3 ligase function, resulting in reduced ubiquitination and enhanced stabilization of MTDH. Elevated MTDH levels then suppressed expression of key ferroptosis inhibitors (SLC3A2 and GPX4), while promoting classical markers of ferroptosis including ROS accumulation, increased free iron, lipid peroxidation (MDA), GSH depletion, and mitochondrial shrinkage. These changes culminated in robust ferroptotic cell death. Importantly, either chemical rescue of ferroptosis or genetic knockdown of MTDH reversed the cytotoxic effects of gramine, demonstrating pathway specificity. In vivo, gramine significantly suppressed TNBC xenograft tumor growth without evident systemic toxicity, underscoring its translational promise. These findings not only clarify the anti-cancer mechanism of gramine but also highlight the CUL3–MTDH axis as a targetable node for ferroptosis-based therapeutic design.

Comparison with Existing Internal Articles

Several internal reviews and research summaries corroborate the mechanistic insights reported in the reference study. For example, one recent article similarly emphasizes the role of CUL3-mediated ubiquitination of MTDH as a central driver of gramine-induced ferroptosis in TNBC, supporting the reproducibility and robustness of this mechanistic model. Additional internal resources, such as the mechanistic analysis and therapeutic perspective, confirm that targeting the CUL3–MTDH axis offers a promising strategy for overcoming chemoresistance and enhancing the efficacy of anti-cancer interventions in aggressive breast cancer subtypes. These articles collectively advance the translational potential of ferroptosis induction as a novel anti-TNBC paradigm.

Limitations and Transferability

While the mechanistic evidence for gramine-induced ferroptosis in TNBC is compelling, several limitations remain. The specificity of gramine for CUL3 relative to other E3 ubiquitin ligases was not exhaustively profiled, and potential off-target effects require further investigation. The majority of functional validation was performed in cell lines and murine models; thus, clinical translatability will depend on additional pharmacokinetic, toxicity, and efficacy studies in humans. The pathway’s relevance in other cancer subtypes or in patient-derived organoids remains to be established. Moreover, the interplay between ferroptosis and other cell death modalities under gramine treatment warrants deeper exploration.

Research Support Resources

Reproducible protein analysis and proteomic workflows are essential for dissecting mechanistic pathways such as those uncovered in this study. When preparing protein samples for immunoblotting, mass spectrometry, or mapping of ubiquitination events, the use of a robust protease mixture is critical. For these purposes, researchers may consider Pronase E (Activity ≥ 7000 U/g) (SKU A9953), a well-characterized protein sample preparation enzyme with broad substrate specificity and high activity. As described in methodological guides and workflow reviews (see here), Pronase E enables efficient proteolytic cleavage, which is crucial for downstream applications such as peptide mapping and proteomics. Note that Pronase E is intended strictly for research use and should be freshly prepared to preserve enzymatic activity. This reagent may help standardize and optimize protein digestion protocols in studies investigating proteome dynamics in cancer and ferroptosis research.